Alpine Immune Sciences Inc. (ALPN)’s Financial Results Comparing With Novan Inc. (NASDAQ:NOVN)

We are contrasting Alpine Immune Sciences Inc. (NASDAQ:ALPN) and Novan Inc. (NASDAQ:NOVN) on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alpine Immune Sciences Inc. 5 142.60 N/A -2.95 0.00
Novan Inc. 2 10.38 N/A -0.56 0.00

Demonstrates Alpine Immune Sciences Inc. and Novan Inc. earnings per share, top-line revenue and valuation.


Table 2 provides Alpine Immune Sciences Inc. and Novan Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Alpine Immune Sciences Inc. 0.00% -78.2% -67.1%
Novan Inc. 0.00% 0% -49.7%


Alpine Immune Sciences Inc.’s Current Ratio and Quick Ratio are 7.3 and 7.3 respectively. The Current Ratio and Quick Ratio of its competitor Novan Inc. are 0.7 and 0.7 respectively. Alpine Immune Sciences Inc. therefore has a better chance of paying off short and long-term obligations compared to Novan Inc.

Institutional and Insider Ownership

Institutional investors owned 46.5% of Alpine Immune Sciences Inc. shares and 5.5% of Novan Inc. shares. 0.1% are Alpine Immune Sciences Inc.’s share owned by insiders. Insiders Competitively, owned 2.4% of Novan Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alpine Immune Sciences Inc. -6.4% 0.95% -33.7% -36.24% -42.39% 15.22%
Novan Inc. 1.15% -2.59% 119.17% 97.74% -2.59% 216.87%

For the past year Alpine Immune Sciences Inc. was less bullish than Novan Inc.


On 4 of the 7 factors Novan Inc. beats Alpine Immune Sciences Inc.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The companyÂ’s product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. The company has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.